Senseonics is set to raise $41 million to support the anticipated commercialization of implantable continuous glucose monitoring (CGM) system Eversense. The fundraising attracted the support of major existing shareholders New Enterprise Associates (NEA) and Roche.
{iframe}http://www.fiercebiotech.com/medtech/roche-helps-senseonics-raise-41m-to-push-diabetes-device{/iframe}